Research indicates that in T2DM patients using SGLT2 inhibitors, the expression of the Scl5a1 gene in the pancreatic islets remains elevated while Scl5a2 gene expression is lower. This evidence concerns the gene SLC5A2 and type 2 diabetes mellitus.